PROTECT Study 1-year results

PROTECT (Progressive Myopia Treatment Evaluation Contact Lens Trial) Study 1-year results for Menicon Bloom Day^TM

The 1-year results further support Menicon Bloom Day^TM as an effective treatment for slowing myopia progression. 

30 January 2024

Menicon Co., Ltd (Head Office: 21-19 Aoi 3, Naka-ku, Nagoya, Japan; President and COO: Koji Kawaura) is pleased to share the 1-year interim retrospective data of the PROTECT randomized controlled trial (RCT) conducted by Visioneering Technologies, Inc., producer of the Menicon Bloom Day^TM contact lens.

Menicon Bloom Day^TM contact lens is the soft daily offering for myopia management included in Menicon Bloom^TM Myopia Control Management System, a holistic approach for myopia control management.

Menicon Bloom Day^TM is a CE-approved contact lens for myopia control.

The analysis of results of the 1-year follow-up shows the treatment effect was 0.41D, or 71% for refractive error, versus the control group. In terms of axial length, the treatment effect was 0.17 mm, or 61%, versus the control group. The average axial length change was 0.11mm in children wearing the Menicon Bloom Day^TM lens. Sixty-four percentage of subjects showed no meaningful progression (0.25D or less).

In conjunction with the previous six-year data1 where the analysis of results of the 1-year follow-up shows the treatment effect was 0.45D for refractive error and 0.17 mm for axial length versus the control group. Another additional independent study2 showed similar results 0.23D for refractive error and 0.17 mm for axial length versus the control group. These results further support Menicon Bloom Day^TM as an effective treatment for slowing myopia progression in children. 

 

Peter Nijhuis
Director Myopia Management Business Division and Menicon Holdings B.V.

"We are thrilled to observe that the one-year data substantiates our confidence in the efficacy of Menicon Bloom Day^TM in slowing myopia progression in young myopic patients. 

At Menicon, we want to support eye care professionals in providing the best tools for myopia management, and these results support our commitment to them and their patients."

 

About Menicon:
Menicon Co., Ltd. (7780: Tokyo), founded by Mr. Kyoichi Tanaka in 1951, is Japan's first and largest contact lens manufacturer and now is represented in over 80 countries. Menicon is a manufacturer dedicated to all areas of soft and gas permeable contact lens-related businesses including manufacturing, sales, export, and import of contact lenses and other medical goods; manufacturing and sales of medical instruments; sales of medical supplies; and research and development of intraocular lenses.

For more information, please visit www.menicon.com.

About Visioneering:
Visioneering Technologies Inc. (ASX: VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing, and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia, and astigmatism. Headquartered in the US, Visioneering designs, manufactures, sells, and distributes contact lenses. Its flagship product is the NaturalVue® MF daily disposable contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

To learn more, please visit www.vtivision.com.

About Menicon & Visioneering Technologies Inc. agreement
For more information: Visioneering Technologies Inc. Press Release

References:

1. Cooper J, O'Connor B, Aller T, Dillehay SM, Weibel K, Benoit D. Reduction of Myopic Progression Using a Multifocal Soft Contact Lens: A Retrospective Cohort Study. Clin Ophthalmol. 2022 Jul 4;16:2145-2155.
2. Cooper J, Aller T, Smith EL 3rd, Chan K, Dillehay SM, O'Connor B. Retrospective Analysis of a Clinical Algorithm for Managing Childhood Myopia Progression. Optom Vis Sci. 2023 Jan 1;100(1):117-124.